Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for viral diseases, announced on September 30, 2014 a definitive agreement with Johnson & Johnson whereby Alios will be acquired for approximately $1.75 billion in cash payable upon closing of the transaction. The transaction has been approved by the boards of directors of both companies.
During the diligence phase of the deal, the Knobbe Martens’ team worked closely with the founders to zealously protect the interests of Alios in its negotiations. “Our portfolio of novel medications targets a diverse range of viral infections, including respiratory syncytial virus, which complements ongoing efforts by Janssen to develop innovative treatments for important and life-threatening infections.” said Lawrence M. Blatt, PhD, President and Chief Executive Officer of Alios BioPharma. “Our robust intellectual property was an important aspect of this transaction. Kimberly J. Miller, Ned Israelsen and the rest of the team at Knobbe Martens have done an excellent job in building a strong patent estate and helping us through the IP due diligence process.”
Alios BioPharma is a clinical stage biopharmaceutical company in South San Francisco, CA that is developing novel therapies for the treatment of viral diseases. The Alios discovery and development platform consists of a proprietary chemical library of nucleoside analogs as well as novel, proprietary virology-based screening systems. Alios is developing a portfolio of potential therapeutics for viral infections including those caused by respiratory syncytial virus, influenza, rhinovirus, coronavirus and HCV. For more information please visit www.aliosbiopharma.com.